2006-2008年长江流域185家医院苯那普利、培哚普利、福辛普利应用情况分析

目的：分析长江流域6城市185家医院以苯那普利、培哚普利和福辛普利为代表的血管紧张素转换酶抑制剂（ACEI）的利用情况及发展趋势。方法：对长江流域6城市185家医院2006--2008年苯那普利、培哚普利和福辛普利的销售金额、用药频度（DDDs）、日均费用及销售金额、DDDs排序分析。结果：长江流域6城市185家医院ACEI制剂销售金额逐年小幅递增，平均增长率为2．41％。苯那普利在上海、杭州、南京、武汉的销售金额及DDDs排序均居第1位，同步性好。结论：长江流域ACEI制剂总体增长趋缓，苯那普利是长江流域地区最常使用的ACEI品种。

Utilization of Benazepril, Perindopril and Fosinopril in 185 Hospitals along the Yangtze Valley from 2006 to 2008

OBJECTIVE： To evaluate the status quo and the tendency of the utilization of benazepril, perindopril and fosinopril in 185 hospitals of 6 cities along the Yangtze Valley. METHODS： The utilization of benazepril, perindopril and fosinopril in 185 hospitals of 6 cities along the Yangtze Valley between 2006 and 2008 were analyzed statistically in respect of the consumption sum, DDC （daily average cost） , ranking of consumption sum and DDDs. RESULTS： The consumption sum of angiotensin-converting enzyme inhibitor（ACEI） witnessed a slight year-on-year increase, up 2.41% on average. In Shanghai, Hangzhou, Nanjing and Wuhan, Benazepril took the lead on the lists of consumption sum and DDDs, showing good synchronicity. CONCLUSION ： The general development of ACEI shows a slowly upward trend in the Yangtze Valley, and Benazepril is the major choice among ACEI used along Yangtze Valley.